Trial Profile

A Phase 2 trial of sonelokimab in n patients with active PsA.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonelokimab (Primary)
Indications Psoriatic arthritis
Focus Therapeutic Use
Acronyms P-OLARIS

Most Recent Events

11 Aug 2026 According to a MoonLake Immunotherapeutics media release, expected to report results from the P-OLARIS trial at the end of 2026 or early 2027.
21 Jun 2026 According to a MoonLake Immunotherapeutics media release, Interim readout of the Phase 2 P-OLARIS trial in PsA and axSpA in H2 2026
21 Jun 2026 Status changed from planning to recruiting as per MoonLake Immunotherapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com